Neurocrine Biosciences Revenue 2010-2022 | NBIX

Neurocrine Biosciences annual/quarterly revenue history and growth rate from 2010 to 2022. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
  • Neurocrine Biosciences revenue for the quarter ending March 31, 2022 was $0.311B, a 31.28% increase year-over-year.
  • Neurocrine Biosciences revenue for the twelve months ending March 31, 2022 was $1.208B, a 15.51% increase year-over-year.
  • Neurocrine Biosciences annual revenue for 2021 was $1.134B, a 8.38% increase from 2020.
  • Neurocrine Biosciences annual revenue for 2020 was $1.046B, a 32.71% increase from 2019.
  • Neurocrine Biosciences annual revenue for 2019 was $0.788B, a 74.67% increase from 2018.
Neurocrine Biosciences Annual Revenue
(Millions of US $)
2021 $1,134
2020 $1,046
2019 $788
2018 $451
2017 $162
2016 $15
2015 $20
2014 $
2013 $3
2012 $53
2011 $77
2010 $34
2009 $3
Neurocrine Biosciences Quarterly Revenue
(Millions of US $)
2022-03-31 $311
2021-12-31 $312
2021-09-30 $296
2021-06-30 $289
2021-03-31 $237
2020-12-31 $248
2020-09-30 $259
2020-06-30 $302
2020-03-31 $237
2019-12-31 $244
2019-09-30 $222
2019-06-30 $184
2019-03-31 $138
2018-12-31 $131
2018-09-30 $152
2018-06-30 $97
2018-03-31 $71
2017-12-31 $95
2017-09-30 $61
2017-06-30 $6
2017-03-31
2016-12-31
2016-09-30
2016-06-30
2016-03-31 $15
2015-12-31
2015-09-30
2015-06-30
2015-03-31 $20
2014-12-31
2014-09-30
2014-06-30
2014-03-31
2013-12-31 $1
2013-09-30 $1
2013-06-30 $1
2013-03-31 $1
2012-12-31 $22
2012-09-30 $9
2012-06-30 $11
2012-03-31 $11
2011-12-31 $11
2011-09-30 $42
2011-06-30 $12
2011-03-31 $13
2010-12-31 $14
2010-09-30 $14
2010-06-30 $5
2010-03-31 $1
2009-12-31 $1
2009-09-30 $1
2009-06-30 $1
2009-03-31 $1
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $8.237B $1.134B
Neurocrine Biosciences is a neuroscience-based company focused on the discovery and development of novel therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases and disorders. The company's neuroscience, endocrine and immunology disciplines provide a unique biological understanding of the molecular interaction between central nervous, immune and endocrine systems for the development of therapeutic interventions for anxiety, depression, insomnia, stroke, malignant brain tumors, multiple sclerosis, obesity and diabetes.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $76.505B 34.15
Takeda Pharmaceutical (TAK) Japan $46.582B 7.83
Catalent (CTLT) United States $17.955B 28.14
Stevanato Group S.p.A (STVN) Italy $5.098B 31.94
Taro Pharmaceutical Industries (TARO) Israel $1.413B 11.53
USANA Health Sciences (USNA) United States $1.330B 12.82
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $1.063B 5.16
Rafael Holdings (RFL) United States $0.036B 0.00
Lannett Co Inc (LCI) United States $0.021B 0.00